These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9869869)

  • 21. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
    Zhu ZX; Fan LY; Wang Q
    Eur Surg Res; 2011; 46(3):109-17. PubMed ID: 21242693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression.
    Kobayashi T; Aomatsu Y; Iwata H; Kin T; Kanehiro H; Hisanaga M; Ko S; Nagao M; Nakajima Y
    Transplantation; 2003 Mar; 75(5):619-25. PubMed ID: 12640299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term observation after simultaneous lung and intra-bone marrow-bone marrow transplantation.
    Kaneda H; Adachi Y; Saito Y; Ikebukuro K; Machida H; Suzuki Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Wang J; Imamura H; Ikehara S
    J Heart Lung Transplant; 2005 Sep; 24(9):1415-23. PubMed ID: 16143265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance induction to islet allografts following infusion of perforin deficient bone marrow.
    Selvaggi G; Inverardi L; Levy RB; Mintz DH; Podack ER; Ricordi C
    Transplant Proc; 1995 Dec; 27(6):3193. PubMed ID: 8539907
    [No Abstract]   [Full Text] [Related]  

  • 25. Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts.
    Li H; Inverardi L; Molano RD; Pileggi A; Ricordi C
    Transplantation; 2003 Apr; 75(7):966-70. PubMed ID: 12698081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing chimerism level through bone marrow transplantation and irradiation to induce long-term tolerance to composite tissue allotransplantation.
    Lin JY; Tsai FC; Wallace CG; Huang WC; Wei FC; Liao SK
    J Surg Res; 2012 Nov; 178(1):487-93. PubMed ID: 22484382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease.
    Gyger M; Baron C; Forest L; Lussier P; Lagacé F; Bissonnette I; Bélanger R; Bonny Y; Busque L; Roy DC; Perreault C
    Exp Hematol; 1998 May; 26(5):426-34. PubMed ID: 9590660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current indications and limits of pancreatic islet transplantation in diabetic nephropathy.
    Masetti M; Inverardi L; Ranuncoli A; Iaria G; Lupo F; Vizzardelli C; Kenyon NS; Alejandro R; Ricordi C
    J Nephrol; 1997; 10(5):245-52. PubMed ID: 9364315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
    O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
    Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed xenogeneic chimerism and tolerance III. A nonlethal approach to induce donor-specific transplantation tolerance to simultaneous islet xenografts.
    Li H; Abou el-Ezz AY; Gambrell BE; Ildstad ST
    Transplantation; 1995 Jul; 60(1):59-65. PubMed ID: 7624944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct characteristics and features of allogeneic chimerism in the NOD mouse model of autoimmune diabetes.
    Zorina TD; Subbotin VM; Bertera S; Alexander AM; Haluszczak C; Styche AJ; Trucco M
    Cell Transplant; 2002; 11(2):113-23. PubMed ID: 12099635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different islet protein expression profiles during spontaneous diabetes development vs. allograft rejection in BB-DP rats.
    Christensen UB; Larsen PM; Fey S; Karlsen AE; Pociot F; Nerup J; Sparre T
    Autoimmunity; 2006 Jun; 39(4):315-21. PubMed ID: 16891220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation.
    Ding Y; Bushell A; Wood KJ
    Transplantation; 2010 Feb; 89(3):270-3. PubMed ID: 20145515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice.
    Deng R; Khattar M; Xie A; Schroder PM; He X; Chen W; Stepkowski SM
    Transplantation; 2014 Jun; 97(12):1216-24. PubMed ID: 24854475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment diabetes by transplantation of insulin secreting cells. Part II--prevention of rejection of the transplanted cells].
    Pokrywczyńska M; Drewa T; Włodarczyk Z; Dufrane D
    Pol Merkur Lekarski; 2006 May; 20(119):619-21. PubMed ID: 16875176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of vascularized bone marrow transplantation: current status and future clinical applications.
    Gordon CR; Tai CY; Suzuki H; Strande LF; Ramsamooj R; Matthews MS; Black KS; Hewitt CW
    Microsurgery; 2007; 27(4):348-53. PubMed ID: 17477415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonobese diabetic natural killer cells: a barrier to allogeneic chimerism that can be reduced by rapamycin.
    Al-Adra DP; Chan WF; Anderson CC
    Transplantation; 2011 Nov; 92(9):977-84. PubMed ID: 21956197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.